Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Solid Tumor 2Neoplasms 2Meningioma 2Breast Neoplasms 2Small Cell Lung Carcinoma 1Recurrence 1Prostatic Neoplasms 1Ovarian Neoplasms 1Non-small Cell Lung Cancer Metastatic 1Neurofibromatosis 2 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Lung Neoplasms 1Fallopian Tube Neoplasms 1Estrogen Receptor Positive Breast Cancer 1Endometrial Neoplasms 1Disease 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Advanced Cancer 1Adenocarcinoma 1

Interventions

Bevacizumab 5Everolimus 4Sirolimus 2Lapatinib 2vistusertib 1temsirolimus 1neratinib 1icotinib 1brigatinib 1Vascular Endothelial Growth Factor A 1Valproic Acid 1Sunitinib 1Immunoglobulin G 1HDAC-42 1Exome 1Endostatins 1Doxycycline 1Disulfides 1Crizotinib 1Cetuximab 1Axitinib 1Aspirin 1AZD 6244 189Zr-bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neurofibromatosis 2 × vistusertib × Clear all
NCT02831257 2022-06-13

AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas

Massachusetts General Hospital

Phase 2 Completed
18 enrolled 13 charts
CNS

Meningioma, Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡